During the corresponding time, Evolus Inc recorded a revenue increase by 21.3 % year on year, sequentially revenue grew by 15.35 %. While revenue at the Evolus Inc 's corporate clients
Evolus Inc's Comment on Sales, Marketing and Customers
The company serves the cash-pay aesthetic market, targeting licensed aesthetic practitioners. Its product portfolio includes injectable neurotoxins and injectable hyaluronic acid (HA) gels. Key products include Jeuveau®, a botulinum toxin type A formulation for the temporary improvement of moderate to severe glabellar lines, marketed in the United States, Canada, select European countries, and Australia. The Evolysse™ line comprises injectable HA gels for various facial areas, with recent regulatory approvals in the European Union and the United States. The company utilizes customer adoption programs such as consumer loyalty initiatives, co-branded marketing, promotional events, and pricing strategies to engage practitioners and patients. The company’s filings reference BOTOX as a customer and market competitor.
Evolus Expands Global Footprint with Multifaceted Initiatives in Aesthetic Medicine NEWPORT BEACH, Calif. Evolus, Inc. (NASDAQ: EOLS), a distinguished player in the performance beauty sector, has made significant strides in expanding its global footprint. This progress is underscored by two pivotal developments: the introduction of Nuceiva (botulinum toxin type A) in France and the strengthening of its financial foundation through a strategic refinancing of its credit facility. Together, these initiatives position Evolus at the forefront of innovation and growth within the aesthetic portfolio of consumer brands.Evolus has partnered with Symatese to begin the distribution of Nuceiva in France, a move that...
In a decisive move to bolster its financial standing, Evolus Inc. (NASDAQ: EOLS), a Newport Beach-based performance beauty company, has announced the successful refinancing of its credit facilities, transitioning from a $125 million credit agreement to a substantial new $250 million facility with Pharmakon Advisors, LP. This strategic shift is set to not only strengthen Evolus’ balance sheet but also enhance its operational flexibility and lower its cost of capital significantly.Announced on May 5th, the new credit agreement marks a pivotal moment for Evolus, which has been on a journey to solidify its position in the competitive aesthetic consumer market. The refinanced credit facility yields a reduction ...
Newport Beach, Calif. - Evolus, Inc. (NASDAQ: EOLS), a performance beauty company dedicated to creating a portfolio of aesthetic consumer brands, has made a significant stride in its strategic growth plan. The company announced the submission of the final module of its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its first two Evolysse dermal filler products: Evolysse Lift and Evolysse Smooth. These products are intended for the treatment of the nasolabial fold (NLF), commonly known as laugh lines or smile lines.We are pleased to have submitted the final module of the PMA application, said Dr. Rui. This milestone marks a crucial step for Evolus as it seeks regulato...
Promising Results of Evolus Evolysse Dermal Filler Products: A Breakthrough in Nasolabial Fold Treatment Evolus, Inc., a renowned performance beauty company, recently announced the positive topline results from a pivotal study of their dermal filler products, Evolysse Lift and Smooth. This achievement marks a significant milestone for the company and reinforces their commitment to developing an aesthetic portfolio of consumer brands. The data from this study were presented at the 2024 SCALE Meeting held in Nashville on May 17, 2024.The nasolabial fold (NLF), commonly referred to as smile or laugh lines, is a significant concern for individuals seeking a more youthful appearance. Evolus has dedicated extensi...
Evolus, Inc., a leading performance beauty company focused on developing a portfolio of aesthetic consumer brands, has recently announced its financial results for the first quarter ended March 31, 2024. Following a record-breaking year in 2023, the company continues to exhibit impressive growth and promising business prospects. This article will delve into Evolus noteworthy performance during the first quarter, highlighting its revenue increase and providing insights into its corporate client base. Evolus Achieves Significant Revenue Growth: During the first quarter of 2024, Evolus reported a remarkable year-on-year revenue increase of 32.78%. This substantial growth demonstrates the company s ability to c...
Evolus Inc’s Comment on Sales, Marketing and Customers
The company serves the cash-pay aesthetic market, targeting licensed aesthetic practitioners. Its product portfolio includes injectable neurotoxins and injectable hyaluronic acid (HA) gels. Key products include Jeuveau®, a botulinum toxin type A formulation for the temporary improvement of moderate to severe glabellar lines, marketed in the United States, Canada, select European countries, and Australia. The Evolysse™ line comprises injectable HA gels for various facial areas, with recent regulatory approvals in the European Union and the United States. The company utilizes customer adoption programs such as consumer loyalty initiatives, co-branded marketing, promotional events, and pricing strategies to engage practitioners and patients. The company’s filings reference BOTOX as a customer and market competitor.
Sources:
Evolus Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Evolus Inc’s corporate clients.
For your research, we’ve provided 9 tables on Evolus Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
185.64 %